Markets
Arvinas Stock Plunges 7%, Wiping Out $35 Million, As Licensing Revenue Dries Up In Third-Quarter Loss
The biotech's revenue fell to $0.5 million after Pfizer-related income ended, though cash is expected to fund operations into 2028.
ARVN
Arvinas (ARVN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Arvinas Third-Quarter Revenue Falls To $0.5 Million From $41.9 Million As Pfizer Income Ends
The biotech's loss widened to $53.9 million, but it says cash of $558.9 million funds operations into the second half of 2028.
Earnings
Arvinas CEO Sets 30% Response Bar For Its First Lymphoma Data In December
Randy Teel says a response rate above 30% at low doses would count as a good showing for ARV-393 in T-cell lymphoma.